论文部分内容阅读
目的 探讨 MDM2、p5 3蛋白在星形细胞瘤发病中的作用及其与肿瘤病理分级、预后的关系。方法 对确诊并有随访的 36例星形细胞瘤标本用免疫组化技术 SABC法进行 MDM2、p5 3蛋白定位观察。结果 发现 MDM2及 p5 3蛋白表达阳性率分别为 44 .4% (16 / 36例 )和 38.9% (14/ 36例 ) ,其阳性率与年龄、性别无关 ,但与肿瘤病理分级呈显著正相关 (分别为 P<0 .0 5 ,P<0 .0 1)。在 36例星形细胞瘤中MDM2和 p5 3共同阳性表达 9例 (2 5 % ) ,这 9例与单独MDM2蛋白或 p5 3蛋白阳性表达病例及 MDM2和 p5 3蛋白表达均阴性病例的一年和三年存活率有显著差别 (分别为P<0 .0 5 ,P<0 .0 1)。结论 MDM2、p5 3蛋白阳性检出率有助于判断星形细胞瘤的恶性程度及预测肿瘤的预后
Objective To investigate the role of MDM2 and p5 3 proteins in the pathogenesis of astrocytoma and its relationship with tumor grade and prognosis. Methods 36 cases of astrocytomas diagnosed and followed up were examined by immunohistochemical technique using SABC method for MDM2 and p5 3 protein. The positive rates of MDM2 and p5 3 protein were 44.4% (16/36) and 38.9% (14/36), respectively. The positive rates of MDM2 and p53 protein were not related to age and gender, but positively correlated with the pathological grade (P <0. 05, P <0. 01, respectively). In 36 cases of astrocytoma, MDM2 and p5 3 were positively expressed in 9 cases (25%). These 9 cases were negative with MDM2 and p5 3 protein positive expression cases either alone or for one year And three-year survival rates were significantly different (P <0.05, P <0.01). Conclusions The positive detection rate of MDM2 and p5 3 protein is helpful to judge the malignant degree of astrocytoma and predict the prognosis of the tumor